Our Pricing

Understanding Wegovy Injection Cost UK: Complete Pricing Guide

Published on: June 03, 2026

Searching for transparent wegovy injection cost uk online information? At Cured Pharmacy, Wegovy (semaglutide) weight loss injections start from £79.00, with all prices displayed upfront before your free clinical consultation. Our UK-registered prescribers assess your suitability in under 3 minutes, and genuine MHRA-licensed medication is dispensed by our GPhC-registered pharmacy team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

What Affects Wegovy Injection Cost UK Pricing?

Wegovy injection cost uk pricing varies based on your prescribed dose strength and treatment duration. Wegovy is available in five escalating doses (0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg), with patients typically starting at the lowest dose and titrating upward over 16-20 weeks to minimise gastrointestinal side effects [1]. Your UK prescriber determines the appropriate dose progression based on your individual response and tolerability.

At Cured Pharmacy, our transparent pricing structure means you see the exact cost before completing your clinical assessment. Unlike traditional high-street pharmacies where pricing remains unclear until collection, we guarantee the lowest prices in the UK with Wegovy starting from £79.00. This includes your medication, prescriber consultation, and discreet home delivery—no hidden fees or surprise charges at checkout.

The monthly wegovy injection cost uk patients pay depends on their current dose tier. Clinical trials show that gradual dose escalation improves treatment adherence and reduces discontinuation rates, making the structured pricing approach both medically sound and financially predictable [1][2].

How Wegovy (Semaglutide) Works for Weight Loss

The Science Behind Semaglutide

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1. This medication works by slowing gastric emptying, reducing appetite signals to the brain, and improving insulin secretion when blood glucose rises [2]. Unlike stimulant-based weight loss treatments, semaglutide addresses multiple metabolic pathways simultaneously.

In the landmark STEP 1 clinical trial, participants using semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo—a clinically significant difference that led to MHRA licensing approval [2]. These results represent some of the most substantial weight loss outcomes seen in pharmaceutical trials to date.

Expected Timeline and Results

Most patients begin noticing appetite reduction within the first 2-4 weeks of treatment, though visible weight loss typically becomes apparent after 8-12 weeks at therapeutic doses [2]. The gradual dose escalation protocol means you'll spend approximately 4 months reaching the maintenance dose of 2.4mg, where maximum efficacy occurs.

Clinical data shows that patients who remain on Wegovy for the full 68-week trial period maintain progressive weight loss, with the greatest reductions occurring between weeks 20 and 60 [2]. Your UK prescriber will monitor your progress through follow-up consultations to ensure optimal dosing and address any side effects promptly.

Wegovy Injection Cost UK Compared to Alternative Treatments

When evaluating wegovy price uk pharmacy options, it's helpful to understand how Wegovy compares to other MHRA-licensed weight loss medications available through UK prescribers. Each treatment offers distinct mechanisms, dosing schedules, and clinical efficacy profiles that influence both suitability and cost-effectiveness.

Saxenda (liraglutide) requires daily injections rather than weekly administration, which some patients find less convenient despite competitive pricing. Mounjaro (tirzepatide) is a newer dual GIP/GLP-1 receptor agonist that demonstrated superior weight loss in head-to-head trials, achieving average reductions of 22.5% body weight in SURPASS-3 compared to semaglutide's 14.9% in STEP trials [3][4]. However, Mounjaro typically carries higher monthly costs reflecting its enhanced efficacy profile.

Oral medications like Mysimba (naltrexone/bupropion combination) and Orlistat offer lower upfront costs but generally produce more modest weight loss—averaging 5-9% body weight reduction in clinical trials [5]. Your choice between these options should balance clinical effectiveness, administration preference, tolerability, and budget considerations during your prescriber consultation.

Who Can Use Wegovy? Eligibility and Safety Considerations

NICE Guidelines and Prescribing Criteria

Wegovy is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea [1]. NICE guidance recommends semaglutide as part of a comprehensive weight management programme that includes dietary modification and increased physical activity.

Your UK prescriber will assess your medical history to identify contraindications, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Wegovy is not suitable during pregnancy or breastfeeding, and patients with a history of pancreatitis require careful evaluation before treatment initiation [1].

Common Side Effects and Management

The most frequently reported side effects of Wegovy are gastrointestinal: nausea (44% of participants), diarrhoea (30%), vomiting (24%), and constipation (24%) in STEP clinical trials [2]. These effects are typically mild to moderate, occurring most commonly during dose escalation, and diminish as your body adapts to the medication.

Our clinical team recommends eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated to minimise digestive discomfort. If side effects become troublesome, your prescriber may slow the dose escalation schedule or temporarily maintain you at a lower dose until tolerability improves. Serious adverse events are rare but require immediate medical attention—contact NHS 111 or your GP if you experience severe abdominal pain, persistent vomiting, or signs of pancreatitis.

How to Start Wegovy Treatment at Cured Pharmacy

Simple Three-Step Process

Beginning your Wegovy journey takes under 3 minutes with our streamlined online consultation. First, complete the confidential medical questionnaire covering your weight history, current medications, and relevant health conditions. Our UK-registered prescribers review every submission individually—there are no automated approvals, ensuring your safety remains the priority.

If Wegovy is deemed clinically appropriate for you, your prescription is sent electronically to our GPhC-registered pharmacy (9012511) where Superintendent Pharmacist Tarun Kumar and his team dispense genuine UK-licensed medication. We use 100% discreet packaging with no external branding, and most orders arrive within 2-4 working days via tracked courier.

Ongoing support is included at no additional cost. You'll receive administration guidance, injection technique videos, and access to our clinical team for any questions during your treatment. Follow-up consultations ensure your dose progression aligns with clinical protocols and your individual response to therapy.

Scientific References

1. Novo Nordisk. (2023). Wegovy 2.4 mg Solution for Injection in Pre-filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
4. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2014). Weight management: lifestyle services for overweight or obese adults (PH53). NICE. https://www.nice.org.uk/guidance/ph53 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and individual results may vary. Treatment suitability is determined by your prescriber based on your medical history and current health status.